{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:33:27Z","timestamp":1792676007603,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,11,19]],"date-time":"2009-11-19T00:00:00Z","timestamp":1258588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1208\/s12248-009-9157-5","type":"journal-article","created":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T20:23:34Z","timestamp":1258575814000},"page":"33-43","source":"Crossref","is-referenced-by-count":280,"title":["Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease"],"prefix":"10.1208","volume":"12","author":[{"given":"Mohammad","family":"Tabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadi Gazit","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Suria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,19]]},"reference":[{"key":"9157_CR1","unstructured":"Humira. Prescribing Information: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3930B1_02_B-Abbott-Humira%20Prescribing%20Info.pdf . 2009."},{"issue":"5","key":"9157_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0091270006298360","volume":"47","author":"MA Mascelli","year":"2007","unstructured":"Mascelli MA, Zhou H, Sweet R, Getsy J, Davis HM, Graham M, et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007;47(5):553\u201365.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"9157_CR3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1177\/0091270009339192","volume":"49","author":"Z Xu","year":"2009","unstructured":"Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-{alpha} human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol. 2009;49(9):1056\u201370.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"9157_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2125.2006.02581.x","volume":"62","author":"I Nestorov","year":"2006","unstructured":"Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol. 2006;62(4):435\u201345.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"9157_CR5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","volume":"45","author":"H Zhou","year":"2005","unstructured":"Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45(5):490\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"9157_CR6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nbt0504-521","volume":"22","author":"IM Tomlinson","year":"2004","unstructured":"Tomlinson IM. Next-generation protein drugs. Nat Biotechnol. 2004;22(5):521\u20132.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"9157_CR7","first-page":"3039","volume":"47","author":"RK Jain","year":"1987","unstructured":"Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12):3039\u201351.","journal-title":"Cancer Res"},{"issue":"4","key":"9157_CR8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF00047468","volume":"6","author":"RK Jain","year":"1987","unstructured":"Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559\u201393.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"9157_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1040-8428(86)80023-3","volume":"5","author":"RK Jain","year":"1986","unstructured":"Jain RK, Gerlowski LE. Extravascular transport in normal and tumor tissues. Crit Rev Oncol Hematol. 1986;5(2):115\u201370.","journal-title":"Crit Rev Oncol Hematol"},{"key":"9157_CR10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/9783527609628.ch12","volume-title":"Pharmacokinetics and pharmacodynamics of biotech drugs","author":"M Tabrizi","year":"2006","unstructured":"Tabrizi M, Roskos LK. Exposure\u2013response relationships for therapeutic biologic products. In: Meibohem B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs. Wiley: New York; 2006. p. 295\u2013327."},{"issue":"1","key":"9157_CR11","first-page":"2","volume":"5","author":"M Tabrizi","year":"2009","unstructured":"Tabrizi M, Suria H. Application of translational biomarkers in development of antibody-based therapeutics. Drug Discov. 2009;5(1): 2\u20136.","journal-title":"Drug Discov"},{"issue":"5\u20136","key":"9157_CR12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drudis.2008.12.008","volume":"14","author":"MA Tabrizi","year":"2009","unstructured":"Tabrizi MA, Bornstein GG, Klakamp SL, Drake A, Knight R, Roskos L. Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov Today. 2009;14(5\u20136):298\u2013305.","journal-title":"Drug Discov Today"},{"issue":"1\u20132","key":"9157_CR13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","volume":"11","author":"MA Tabrizi","year":"2006","unstructured":"Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1\u20132):81\u20138.","journal-title":"Drug Discov Today"},{"issue":"11","key":"9157_CR14","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645\u201368.","journal-title":"J Pharm Sci"},{"issue":"3","key":"9157_CR15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.1994.134","volume":"56","author":"G Levy","year":"1994","unstructured":"Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"9157_CR16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","volume":"28","author":"DE Mager","year":"2001","unstructured":"Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507\u201332.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"21\u201322","key":"9157_CR17","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.drudis.2007.08.009","volume":"12","author":"JR Desjarlais","year":"2007","unstructured":"Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today. 2007;12(21\u201322):898\u2013910.","journal-title":"Drug Discov Today"},{"issue":"1","key":"9157_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","volume":"24","author":"F Nimmerjahn","year":"2006","unstructured":"Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24(1):19\u201328.","journal-title":"Immunity"},{"key":"9157_CR19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","volume":"19","author":"JV Ravetch","year":"2001","unstructured":"Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275\u201390.","journal-title":"Annu Rev Immunol"},{"issue":"3 Suppl","key":"9157_CR20","first-page":"814s","volume":"50","author":"RK Jain","year":"1990","unstructured":"Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50(3 Suppl):814s\u20139s.","journal-title":"Cancer Res"},{"issue":"3","key":"9157_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0192-0561(92)90176-L","volume":"14","author":"JN Weinstein","year":"1992","unstructured":"Weinstein JN, van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol. 1992;14(3):457\u201363.","journal-title":"Int J Immunopharmacol"},{"issue":"12","key":"9157_CR22","first-page":"3487","volume":"50","author":"MA Clauss","year":"1990","unstructured":"Clauss MA, Jain RK. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. Cancer Res. 1990;50(12):3487\u201392.","journal-title":"Cancer Res"},{"issue":"2","key":"9157_CR23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/pr.57.2.4","volume":"57","author":"BT Hawkins","year":"2005","unstructured":"Hawkins BT, Davis TP. The blood\u2013brain barrier\/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173\u201385.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"9157_CR24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00618781","volume":"20","author":"M Gibaldi","year":"1981","unstructured":"Gibaldi M, Koup JR. Pharmacokinetic concepts\u2014drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol. 1981;20(4):299\u2013305.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7473","key":"9157_CR25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(66)92190-8","volume":"2","author":"FW Brambell","year":"1966","unstructured":"Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet. 1966;2(7473):1087\u201393.","journal-title":"Lancet"},{"issue":"12","key":"9157_CR26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0167-5699(97)01172-9","volume":"18","author":"V Ghetie","year":"1997","unstructured":"Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today. 1997;18(12):592\u20138.","journal-title":"Immunol Today"},{"key":"9157_CR27","first-page":"33","volume-title":"Immunoglobulins: biological aspects and clinical uses","author":"TA Waldmann","year":"1970","unstructured":"Waldmann TA. Variations in the metabolism of immunoglobulins measured by turnover rates. In: Merler E, editor. Immunoglobulins: biological aspects and clinical uses. Washington, DC: National Academy of Sciences; 1970. p. 33\u201351."},{"issue":"10","key":"9157_CR28","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood.V98.10.3136","volume":"98","author":"WK Bleeker","year":"2001","unstructured":"Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood. 2001;98(10):3136\u201342.","journal-title":"Blood"},{"issue":"6","key":"9157_CR29","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1182\/blood.V100.6.2087","volume":"100","author":"RJ Hansen","year":"2002","unstructured":"Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002;100(6):2087\u201393.","journal-title":"Blood"},{"issue":"5","key":"9157_CR30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10928-007-9065-1","volume":"34","author":"A Garg","year":"2007","unstructured":"Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687\u2013709.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"20\u201321","key":"9157_CR31","first-page":"825","volume":"113","author":"M Haas de","year":"2001","unstructured":"de Haas M. IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien Klin Wochenschr. 2001;113(20\u201321):825\u201331.","journal-title":"Wien Klin Wochenschr"},{"key":"9157_CR32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1749-6632.1997.tb52070.x","volume":"815","author":"A Rascu","year":"1997","unstructured":"Rascu A, Repp R, Westerdaal NA, Kalden JR, van de Winkel JG. Clinical relevance of Fc gamma receptor polymorphisms. Ann N Y Acad Sci. 1997;815:282\u201395.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"9157_CR33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc1292","volume":"4","author":"JM Woof","year":"2004","unstructured":"Woof JM, Burton DR. Human antibody\u2013Fc receptor interactions illuminated by crystal structures. Nat Rev. 2004;4(2):89\u201399.","journal-title":"Nat Rev"},{"issue":"3","key":"9157_CR34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2001.19.3.851","volume":"19","author":"K Margolin","year":"2001","unstructured":"Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9157_CR35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2125.2006.02803.x","volume":"63","author":"N Hayashi","year":"2007","unstructured":"Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007;63(5):548\u201361.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9157_CR36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/72601","volume":"18","author":"TW Chang","year":"2000","unstructured":"Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000;18(2):157\u201362.","journal-title":"Nat Biotechnol"},{"issue":"25","key":"9157_CR37","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","volume":"354","author":"RC Strunk","year":"2006","unstructured":"Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354(25):2689\u201395.","journal-title":"N Engl J Med"},{"issue":"8 Pt 2","key":"9157_CR38","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1164\/ajrccm.164.supplement_1.2103026","volume":"164","author":"WW Busse","year":"2001","unstructured":"Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S12\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"9157_CR39","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","volume":"341","author":"H Milgrom","year":"1999","unstructured":"Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341(26):1966\u201373.","journal-title":"N Engl J Med"},{"issue":"33","key":"9157_CR40","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1021\/bi00033a020","volume":"34","author":"J Liu","year":"1995","unstructured":"Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 1995;34(33):10474\u201382.","journal-title":"Biochemistry"},{"issue":"2","key":"9157_CR41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1208\/s12248-008-9045-4","volume":"10","author":"WS Putnam","year":"2008","unstructured":"Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J. 2008;10(2):425\u201330.","journal-title":"AAPS J"},{"issue":"2","key":"9157_CR42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S1081-1206(10)61928-X","volume":"89","author":"SG Johansson","year":"2002","unstructured":"Johansson SG, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002;89(2):132\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4 Suppl","key":"9157_CR43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.10301","volume":"94","author":"A Johansson","year":"2002","unstructured":"Johansson A, Erlandsson A, Eriksson D, Ullen A, Holm P, Sundstrom BE, et al. Idiotypic\u2013anti-idiotypic complexes and their in vivo metabolism. Cancer. 2002;94(4 Suppl):1306\u201313.","journal-title":"Cancer"},{"issue":"2","key":"9157_CR44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/cbr.2009.0627","volume":"24","author":"SI Rudnick","year":"2009","unstructured":"Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24(2):155\u201361.","journal-title":"Cancer Biother Radiopharm"},{"issue":"12","key":"9157_CR45","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421\u201334.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"9157_CR46","first-page":"57","volume":"29","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29(2):57\u201361.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"9157_CR47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2967\/jnumed.106.037069","volume":"48","author":"GM Thurber","year":"2007","unstructured":"Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med. 2007;48(6):995\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"9157_CR48","first-page":"1288","volume":"63","author":"CP Graff","year":"2003","unstructured":"Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003;63(6):1288\u201396.","journal-title":"Cancer Res"},{"issue":"1","key":"9157_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","volume":"271","author":"RK Jain","year":"1994","unstructured":"Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271(1):58\u201365.","journal-title":"Sci Am"},{"issue":"1","key":"9157_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10739689709148314","volume":"4","author":"RK Jain","year":"1997","unstructured":"Jain RK. The Eugene M, Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 1997;4(1):1\u201323.","journal-title":"Microcirculation"},{"issue":"4","key":"9157_CR51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrc778","volume":"2","author":"RK Jain","year":"2002","unstructured":"Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2002;2(4):266\u201376.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"9157_CR52","first-page":"4324","volume":"60","author":"AJ Leu","year":"2000","unstructured":"Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000;60(16):4324\u20137.","journal-title":"Cancer Res"},{"issue":"10","key":"9157_CR53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure\u2014an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806\u201313.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"9157_CR54","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2418::AID-CNCR16>3.0.CO;2-S","volume":"82","author":"MF Milosevic","year":"1998","unstructured":"Milosevic MF, Fyles AW, Wong R, Pintilie M, Kavanagh MC, Levin W, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer. 1998;82(12):2418\u201326.","journal-title":"Cancer"},{"issue":"3","key":"9157_CR55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1349-7006.1990.tb02562.x","volume":"81","author":"K Hori","year":"1990","unstructured":"Hori K, Suzuki M, Tanda S, Saito S. In vivo analysis of tumor vascularization in the rat. Jpn J Cancer Res. 1990;81(3):279\u201388.","journal-title":"Jpn J Cancer Res"},{"issue":"3","key":"9157_CR56","first-page":"815","volume":"150","author":"AR Perez-Atayde","year":"1997","unstructured":"Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815\u201321.","journal-title":"Am J Pathol"},{"issue":"1","key":"9157_CR57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/bies.950130106","volume":"13","author":"RS Kerbel","year":"1991","unstructured":"Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays. 1991;13(1):31\u20136.","journal-title":"BioEssays"},{"issue":"18","key":"9157_CR58","first-page":"5381","volume":"62","author":"DM McDonald","year":"2002","unstructured":"McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62(18):5381\u20135.","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"9157_CR59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1026529222845","volume":"19","author":"DM McDonald","year":"2000","unstructured":"McDonald DM, Foss AJ. Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev. 2000;19(1\u20132):109\u201320.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"9157_CR60","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9440(10)64920-6","volume":"160","author":"S Morikawa","year":"2002","unstructured":"Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160(3):985\u20131000.","journal-title":"Am J Pathol"},{"issue":"6801","key":"9157_CR61","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249\u201357.","journal-title":"Nature"},{"key":"9157_CR62","first-page":"97","volume":"237","author":"HF Dvorak","year":"1999","unstructured":"Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor\/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999;237:97\u2013132.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"9157_CR63","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","volume":"156","author":"H Hashizume","year":"2000","unstructured":"Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156(4):1363\u201380.","journal-title":"Am J Pathol"},{"issue":"8","key":"9157_CR64","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","volume":"95","author":"SK Hobbs","year":"1998","unstructured":"Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95(8):4607\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"9157_CR65","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"9157_CR66","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nm879","volume":"9","author":"E Brown","year":"2003","unstructured":"Brown E, McKee T, diTomaso E, Pluen A, Seed B, Boucher Y, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003;9(6):796\u2013800.","journal-title":"Nat Med"},{"issue":"10","key":"9157_CR67","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/sj.bjc.6600270","volume":"86","author":"C de L Davies","year":"2002","unstructured":"Davies C de L, Berk DA, Pluen A, Jain RK. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer. 2002;86(10):1639\u201344.","journal-title":"Br J Cancer"},{"issue":"9","key":"9157_CR68","first-page":"2497","volume":"60","author":"PA Netti","year":"2000","unstructured":"Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60(9):2497\u2013503.","journal-title":"Cancer Res"},{"issue":"11","key":"9157_CR69","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","volume":"4","author":"RA Gatenby","year":"2004","unstructured":"Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"9157_CR70","first-page":"4373","volume":"49","author":"IF Tannock","year":"1989","unstructured":"Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49(16):4373\u201384.","journal-title":"Cancer Res"},{"issue":"3","key":"9157_CR71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00046364","volume":"9","author":"RK Jain","year":"1990","unstructured":"Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9(3):253\u201366.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"9157_CR72","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/314523","volume":"178","author":"R Malley","year":"1998","unstructured":"Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178(6):1555\u201361.","journal-title":"J Infect Dis"},{"key":"9157_CR73","first-page":"103","volume":"317","author":"H Wu","year":"2008","unstructured":"Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103\u201323.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"2","key":"9157_CR74","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mai.2001.116576","volume":"108","author":"TK Hart","year":"2001","unstructured":"Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol. 2001;108(2):250\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"33","key":"9157_CR75","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall'Acqua","year":"2006","unstructured":"Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514\u201324.","journal-title":"J Biol Chem"},{"issue":"3","key":"9157_CR76","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","volume":"368","author":"H Wu","year":"2007","unstructured":"Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368(3):652\u201365.","journal-title":"J Mol Biol"},{"issue":"1","key":"9157_CR77","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jmb.2005.04.049","volume":"350","author":"H Wu","year":"2005","unstructured":"Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol. 2005;350(1):126\u201344.","journal-title":"J Mol Biol"},{"issue":"4","key":"9157_CR78","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.21749","volume":"54","author":"BW Kirkham","year":"2006","unstructured":"Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006;54(4):1122\u201331.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"9157_CR79","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345\u201352.","journal-title":"J Clin Invest"},{"issue":"9625","key":"9157_CR80","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double- blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384.","journal-title":"Lancet"},{"key":"9157_CR81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","volume":"223","author":"LA Tesmer","year":"2008","unstructured":"Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87\u2013113.","journal-title":"Immunol Rev"},{"issue":"3","key":"9157_CR82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/joca.1999.0292","volume":"8","author":"CI Westacott","year":"2000","unstructured":"Westacott CI, Barakat AF, Wood L, Perry MJ, Neison P, Bisbinas I, et al. Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthr Cartil. 2000;8(3):213\u201321.","journal-title":"Osteoarthr Cartil"},{"issue":"10","key":"9157_CR83","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/rheumatology\/39.10.1139","volume":"39","author":"EH Choy","year":"2000","unstructured":"Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, Kingsley GH, et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford, England). 2000;39(10):1139\u201346.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"11","key":"9157_CR84","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/ard.2007.072447","volume":"66","author":"W Kievit","year":"2007","unstructured":"Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66(11):1473\u20138.","journal-title":"Ann Rheum Dis"},{"key":"9157_CR85","unstructured":"Enbrel. Prescribing Information: http:\/\/www.enbrel.com\/pdf\/enbrel_pi.pdf . 2009."},{"key":"9157_CR86","unstructured":"Remicade. Prescribing Information: http:\/\/www.medversation.com\/medversation\/assets\/PI_MedGuides_External\/REMICADE_PI.pdf . 2009."},{"key":"9157_CR87","unstructured":"SIMPONI. Prescribing Information: http:\/\/www.centocoraccessone.com\/centocoraccessone\/assets\/simponi\/SIMPONI.pdf . 2009."},{"issue":"9","key":"9157_CR88","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","volume":"24","author":"WM Pardridge","year":"2007","unstructured":"Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733\u201344.","journal-title":"Pharm Res"},{"issue":"2","key":"9157_CR89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","volume":"101","author":"JL Rubenstein","year":"2003","unstructured":"Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466\u20138.","journal-title":"Blood"},{"issue":"3","key":"9157_CR90","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/IAI.26.3.933-941.1979","volume":"26","author":"WP Kaschka","year":"1979","unstructured":"Kaschka WP, Theilkaes L, Eickhoff K, Skvaril F. Disproportionate elevation of the immunoglobulin G1 concentration in cerebrospinal fluids of patients with multiple sclerosis. Infect Immun. 1979;26(3):933\u201341.","journal-title":"Infect Immun"},{"issue":"1","key":"9157_CR91","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1471-4159.2002.00840.x","volume":"81","author":"F Schlachetzki","year":"2002","unstructured":"Schlachetzki F, Zhu C, Pardridge WM. Expression of the neonatal Fc receptor (FcRn) at the blood\u2013brain barrier. J Neurochem. 2002;81(1):203\u20136.","journal-title":"J Neurochem"},{"issue":"1","key":"9157_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","volume":"16","author":"P Ballabh","year":"2004","unstructured":"Ballabh P, Braun A, Nedergaard M. The blood\u2013brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol dis. 2004;16(1):1\u201313.","journal-title":"Neurobiol dis"},{"issue":"1\u20132","key":"9157_CR93","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0165-5728(01)00242-9","volume":"114","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood\u2013brain barrier. J Neuroimmunol. 2001;114(1\u20132):168\u201372.","journal-title":"J Neuroimmunol"},{"issue":"50","key":"9157_CR94","doi-asserted-by":"crossref","first-page":"11495","DOI":"10.1523\/JNEUROSCI.3697-05.2005","volume":"25","author":"R Deane","year":"2005","unstructured":"Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood\u2013brain barrier neonatal Fc receptor. J Neurosci. 2005;25(50):11495\u2013503.","journal-title":"J Neurosci"},{"issue":"2","key":"9157_CR95","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/bc060349x","volume":"18","author":"RJ Boado","year":"2007","unstructured":"Boado RJ, Zhang Y, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood\u2013brain barrier and Abeta fibril disaggregation. Bioconjug Chem. 2007;18(2):447\u201355.","journal-title":"Bioconjug Chem"},{"key":"9157_CR96","unstructured":"Avastin. Prescribing Information: http:\/\/www.gene.com\/gene\/products\/information\/pdf\/avastin-prescribing.pdf . 2009."},{"issue":"6","key":"9157_CR97","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.2007.15.1605","volume":"26","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol. 2008;26(6):1012\u20133. author reply 3.","journal-title":"J Clin Oncol"},{"issue":"30","key":"9157_CR98","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9157_CR99","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nurt.2009.04.001","volume":"6","author":"MC Tate","year":"2009","unstructured":"Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics. 2009;6(3):447\u201357.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"9157_CR100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00401-002-0524-x","volume":"104","author":"G Rascher","year":"2002","unstructured":"Rascher G, Fischmann A, Kroger S, Duffner F, Grote EH, Wolburg H. Extracellular matrix and the blood\u2013brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 2002;104(1):85\u201391.","journal-title":"Acta Neuropathol"},{"issue":"21","key":"9157_CR101","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1212\/01.wnl.0000262031.18018.1a","volume":"68","author":"GL Bowman","year":"2007","unstructured":"Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood\u2013brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68(21):1809\u201314.","journal-title":"Neurology"},{"key":"9157_CR102","unstructured":"Bapineuzumab. http:\/\/www.wyeth.nl\/Portals\/0\/downloads\/pers\/persberichten\/Bapi%20P2%20FINAL%20 -- %2028July08.pdf . 2008."},{"issue":"2","key":"9157_CR103","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1172\/JCI111428","volume":"74","author":"LM Nadler","year":"1984","unstructured":"Nadler LM, Korsmeyer SJ, Anderson KC, Boyd AW, Slaughenhoupt B, Park E, et al. B cell origin of non-T cell acute lymphoblastic leukemia a model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984;74(2):332\u201340.","journal-title":"J Clin Invest"},{"issue":"1","key":"9157_CR104","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4049\/jimmunol.131.1.232","volume":"131","author":"P Rosenthal","year":"1983","unstructured":"Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Osathanondh R, Schlossman SF, et al. Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol. 1983;131(1):232\u20137.","journal-title":"J Immunol"},{"issue":"4","key":"9157_CR105","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678\u201385.","journal-title":"J Immunol"},{"issue":"8","key":"9157_CR106","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825\u201333.","journal-title":"J Clin Oncol"},{"issue":"8","key":"9157_CR107","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.intimp.2004.04.015","volume":"4","author":"Y Vugmeyster","year":"2004","unstructured":"Vugmeyster Y, Howell K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol. 2004;4(8):1117\u201324.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"9157_CR108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cyto.a.10030","volume":"52","author":"Y Vugmeyster","year":"2003","unstructured":"Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A. 2003;52(2):101\u20139.","journal-title":"Cytometry A"},{"issue":"10\u201311","key":"9157_CR109","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S1567-5769(03)00147-4","volume":"3","author":"Y Vugmeyster","year":"2003","unstructured":"Vugmeyster Y, Howell K, McKeever K, Combs D, Canova-Davis E. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol. 2003;3(10\u201311):1477\u201381.","journal-title":"Int Immunopharmacol"},{"key":"9157_CR110","doi-asserted-by":"publisher","unstructured":"Bornstein GG, Queva C, Tabrizi M, van Abbema A, Chavez C, Wang P, et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Invest New Drugs. 2009. doi: 10.1007\/s10637-009-9291-z .","DOI":"10.1007\/s10637-009-9291-z"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-009-9157-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-009-9157-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-009-9157-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-009-9157-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T12:11:26Z","timestamp":1685189486000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-009-9157-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,19]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["9157"],"URL":"https:\/\/doi.org\/10.1208\/s12248-009-9157-5","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,19]]}}}